{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:39:59Z","timestamp":1772735999212,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Valle d\u2019Aosta (Italy) has been recognized as the region reporting the lowest level of lipid-lowering drug use in the country, according to the Italian Medicines Agency. This retrospective, observational study investigated medication adherence and time to initiation (TTI) for lipid-lowering drug dispensing, based on medication supplies from hospital and community pharmacies, among residents of the Valle d\u2019Aosta Region in secondary prevention of diseases associated with atherosclerotic cardiovascular disease (ASCVD) and na\u00efve to lipid-lowering drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Anonymized data relating to drug dispensing and hospitalizations from the local health authority of the Valle d\u2019Aosta (AUSL VdA) were collected during 2016\u201322. Data were used to estimate adherence to lipid-lowering drugs, measured as the medication possession ratio (MPR) and the TTI after the first hospital discharge for ASCVD-related conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>A total of 426 patients were included in the study (median age 67.0\u00a0years, 68.3% males). Adherence to lipid-lowering treatment was suboptimal, with only 43.7% of analysed patients classified as adherent during 3 years after initiation (MPR\u2009\u2265\u200980.0%). Among them, median TTI was 72.5\u00a0days, with only 14.1% initiating lipid-lowering drug dispensing by community pharmacies within the first week post-discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The low consumption of lipid-lowering drugs observed in the region finds a counterpart in the context of poor adherence and of delay in therapy initiation in secondary prevention patients described by this analysis. The findings highlight the need for new strategies to mitigate ASCVD-related risks. Insights from this study may guide regional healthcare providers in implementing targeted interventions to enhance cardiovascular outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riag028","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:43:08Z","timestamp":1771418588000},"source":"Crossref","is-referenced-by-count":0,"title":["Medication adherence and time to initiation of lipid-lowering drug dispensing by pharmacies in the Valle d\u2019Aosta region (Italy) in patients with conditions associated with atherosclerotic cardiovascular diseases"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-8047","authenticated-orcid":false,"given":"Lucrezia Greta","family":"Armando","sequence":"first","affiliation":[{"name":"Department of Drug Science and Technology, University of Turin , Via Pietro Giuria 9, 10125 Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Luboz","sequence":"additional","affiliation":[{"name":"Struttura Complessa Farmacia Azienda USL Valle d\u2019Aosta , Via Guido Rey 1, 11100 Aosta ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Russo","sequence":"additional","affiliation":[{"name":"Struttura Complessa Farmacia Azienda USL Valle d\u2019Aosta , Via Guido Rey 1, 11100 Aosta ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enza","family":"Agostino","sequence":"additional","affiliation":[{"name":"Struttura Complessa Farmacia Azienda USL Valle d\u2019Aosta , Via Guido Rey 1, 11100 Aosta ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fadda","sequence":"additional","affiliation":[{"name":"Struttura Complessa Farmacia Azienda USL Valle d\u2019Aosta , Via Guido Rey 1, 11100 Aosta ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-2099","authenticated-orcid":false,"given":"Gianluca","family":"Miglio","sequence":"additional","affiliation":[{"name":"Department of Drug Science and Technology, University of Turin , Via Pietro Giuria 9, 10125 Turin ,","place":["Italy"]},{"name":"Competence Centre for Scientific Computing, University of Turin , Corso Svizzera 185, 10126 Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3718-7537","authenticated-orcid":false,"given":"Clara","family":"Cena","sequence":"additional","affiliation":[{"name":"Department of Drug Science and Technology, University of Turin , Via Pietro Giuria 9, 10125 Turin ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"2026030512504263100_ref1","doi-asserted-by":"publisher","first-page":"e35463","DOI":"10.7759\/cureus.35463","article-title":"A systematic review of lipid management in secondary prevention and comparison of international lipid management pathways","volume":"15","author":"Khan","year":"2023","journal-title":"Cureus"},{"key":"2026030512504263100_ref2","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/jcm10040886","article-title":"Lipid-lowering therapy in patients with coronary heart disease and prior stroke: Mission impossible?","volume":"10","author":"Temporelli","year":"2021","journal-title":"J Clin Med"},{"key":"2026030512504263100_ref3","author":"American Heart Association"},{"key":"2026030512504263100_ref4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/jcm13072043","article-title":"Lipid-lowering therapy after acute coronary syndrome","volume":"13","author":"Pogran","year":"2024","journal-title":"J Clin Med"},{"key":"2026030512504263100_ref5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1714\/3605.35841","article-title":"Prevenzione Italia 2021. Un update del Documento di consenso e raccomandazioni per la prevenzione cardiovascolare in Italia","volume":"22","author":"Battistoni","year":"2021","journal-title":"G Ital Cardiol"},{"key":"2026030512504263100_ref6","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"2026030512504263100_ref7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026030512504263100_ref8","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026030512504263100_ref9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026030512504263100_ref10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/clc.23160","article-title":"Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population","volume":"42","author":"Li","year":"2019","journal-title":"Clin Cardiol"},{"key":"2026030512504263100_ref11","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ehjacc\/zuac123","article-title":"Acute LDL-C reduction post ACS: strike early and strike strong: from evidence to clinical practice. A clinical consensus statement of the Association for Acute CardioVascular care (ACVC), in collaboration with the European Association of Preventive Cardiology (EAPC) and the European Society of Cardiology Working Group on cardiovascular pharmacotherapy","volume":"11","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026030512504263100_ref12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/ehjcvp\/pvaa010","article-title":"Low adherence to statin treatment during the 1st year after an acute myocardial infarction is associated with increased 2nd-year mortality risk \u2013 an inverse probability of treatment weighted study on 54872 patients","volume":"7","author":"Khalaf","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026030512504263100_ref13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/archinte.166.17.1814","article-title":"The effect of early, intensive statin therapy on acute coronary syndrome","volume":"166","author":"Hulten","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026030512504263100_ref14","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/jamacardio.2018.4936","article-title":"Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease","volume":"4","author":"Rodriguez","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026030512504263100_ref15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.4070\/kcj.2018.0341","article-title":"Benefit of early statin initiation within 48 hours after admission in statin-na\u00efve patients with acute myocardial infarction undergoing percutaneous coronary intervention","volume":"49","author":"Kim","year":"2019","journal-title":"Korean Circ J"},{"key":"2026030512504263100_ref16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1111\/bcp.14659","article-title":"TEOS: a framework for constructing operational definitions of medication adherence based on timelines-events-objectives-sources","volume":"87","author":"Dima","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026030512504263100_ref17","volume-title":"Guidelines for ATC Classification and DDD Assignment","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2024"},{"key":"2026030512504263100_ref18","author":"Ministero del Lavoro, della Salute e delle Politiche Sociali","year":"2007"},{"key":"2026030512504263100_ref19","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jacc.2015.01.028","article-title":"Hospital length of stay and clinical outcomes in older STEMI patients after primary PCI","volume":"65","author":"Swaminathan","year":"2015","journal-title":"JACC"},{"key":"2026030512504263100_ref20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/pharmaceutics14010103","article-title":"Delta T, a useful indicator for pharmacy dispensing data to monitor medication adherence","volume":"14","author":"Baumgartner","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026030512504263100_ref21","author":"Dediu","year":"2025"},{"key":"2026030512504263100_ref22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2125.2006.02801.x","article-title":"Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage","volume":"63","author":"Poluzzi","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"2026030512504263100_ref23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00228-007-0428-8","article-title":"Adherence to statin therapy and patients\u2019 cardiovascular risk: a pharmacoepidemiological study in Italy","volume":"64","author":"Poluzzi","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2026030512504263100_ref24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2018.12.026","article-title":"Adherence and persistence to hyperlipidemia medications in patients with atherosclerotic cardiovascular disease and those with diabetes mellitus based on administrative claims data in Japan","volume":"282","author":"Wake","year":"2019","journal-title":"Atherosclerosis"},{"key":"2026030512504263100_ref25","volume-title":"L\u2019uso Dei Farmaci in Italia. Rapporto Nazionale Anno 2019","author":"Osservatorio Nazionale sull\u2019impiego dei Medicinali","year":"2020"},{"key":"2026030512504263100_ref26","article-title":"R: a language and environment for statistical computing (version 4.0.5)","author":"R Core Team","year":"2021","journal-title":"Comput Softw"},{"key":"2026030512504263100_ref27","author":"Ministero della Salute","year":"2022"},{"key":"2026030512504263100_ref28","doi-asserted-by":"publisher","first-page":"S2149","DOI":"10.21037\/jtd.2018.06.46","article-title":"Timing of high intensity statin for acute coronary syndrome: how earlier initiation makes better?","volume":"10","author":"Kim","year":"2018","journal-title":"J Thorac Dis"},{"key":"2026030512504263100_ref29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjcard.2005.07.135","article-title":"Association between time of statin initiation after hospital discharge from acute myocardial infarction and risk of recurrence and mortality in patients \u226565 years of age","volume":"97","author":"Zhou","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026030512504263100_ref30","doi-asserted-by":"publisher","first-page":"e020893","DOI":"10.1161\/JAHA.120.0200893","article-title":"What do US physicians and patients think about lipid-lowering therapy and goal of treatment? Results from the GOULD registry","volume":"10","author":"Arnold","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026030512504263100_ref31","volume-title":"L\u2019uso Dei Farmaci in Italia. Rapporto Nazionale Anno 2022","author":"Osservatorio Nazionale sull\u2019impiego dei Medicinali","year":"2023"},{"key":"2026030512504263100_ref32","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"2026030512504263100_ref33","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/eurheartj\/ehu080","article-title":"Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry","volume":"35","author":"Kumbhani","year":"2014","journal-title":"Eur Heart J"},{"key":"2026030512504263100_ref34","doi-asserted-by":"publisher","first-page":"3856242","DOI":"10.1155\/2020\/3856242","article-title":"Lipid lowering treatment and eligibility for PCSK9 inhibition in post-myocardial infarction patients in Italy: insights from two contemporary Nationwide registries","volume":"2020","author":"Colivicchi","year":"2020","journal-title":"Cardiovasc Ther"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag028\/67244537\/riag028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag028\/67244537\/riag028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:50:49Z","timestamp":1772733049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article\/doi\/10.1093\/ijpp\/riag028\/8507407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riag028","relation":{},"ISSN":["0961-7671","2042-7174"],"issn-type":[{"value":"0961-7671","type":"print"},{"value":"2042-7174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"riag028"}}